155 related articles for article (PubMed ID: 28000159)
1. HER3 as a Therapeutic Target in Cancer.
Karachaliou N; Lazzari C; Verlicchi A; Sosa AE; Rosell R
BioDrugs; 2017 Feb; 31(1):63-73. PubMed ID: 28000159
[TBL] [Abstract][Full Text] [Related]
2. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
3. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
4. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathways: HER3 targeted therapy.
Gala K; Chandarlapaty S
Clin Cancer Res; 2014 Mar; 20(6):1410-6. PubMed ID: 24520092
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
7. HER3/ErbB3, an emerging cancer therapeutic target.
Zhang N; Chang Y; Rios A; An Z
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):39-48. PubMed ID: 26496898
[TBL] [Abstract][Full Text] [Related]
8. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
9. A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy.
Claus J; Patel G; Ng T; Parker PJ
Biochem Soc Trans; 2014 Aug; 42(4):831-6. PubMed ID: 25109965
[TBL] [Abstract][Full Text] [Related]
10. Targeting HER proteins in cancer therapy and the role of the non-target HER3.
Hsieh AC; Moasser MM
Br J Cancer; 2007 Aug; 97(4):453-7. PubMed ID: 17667926
[TBL] [Abstract][Full Text] [Related]
11. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
[TBL] [Abstract][Full Text] [Related]
12. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance.
Temraz S; Mukherji D; Shamseddine A
Crit Rev Oncol Hematol; 2016 May; 101():151-7. PubMed ID: 27017409
[TBL] [Abstract][Full Text] [Related]
14. HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer.
Majumder A
Cells; 2023 Oct; 12(21):. PubMed ID: 37947595
[TBL] [Abstract][Full Text] [Related]
15. The role of HER3 in gastric cancer.
Wang L; Yuan H; Li Y; Han Y
Biomed Pharmacother; 2014 Jul; 68(6):809-12. PubMed ID: 25194439
[TBL] [Abstract][Full Text] [Related]
16. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
[TBL] [Abstract][Full Text] [Related]
17. Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics.
Sims JD; Taguiam JM; Alonso-Valenteen F; Markman J; Agadjanian H; Chu D; Lubow J; Abrol R; Srinivas D; Jain A; Han B; Qu Y; Mirzadehgan P; Hwang JY; Rentsendorj A; Chung A; Lester J; Karlan BY; Gray HB; Gross Z; Giuliano A; Cui X; Medina-Kauwe LK
J Control Release; 2018 Feb; 271():127-138. PubMed ID: 29288681
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
[TBL] [Abstract][Full Text] [Related]
19. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
[TBL] [Abstract][Full Text] [Related]
20. Targeting HER3 for cancer treatment: a new horizon for an old target.
Uliano J; Corvaja C; Curigliano G; Tarantino P
ESMO Open; 2023 Feb; 8(1):100790. PubMed ID: 36764093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
